The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Clinical research
Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial
EuroIntervention 2013;9:328-335 published online ahead of print March 2013. DOI: 10.4244/EIJV9I3A54
Pilar Jiménez-Quevedo1, MD, PhD; Lorenzo Hernando1, MD; Joan Antoni Gómez-Hospital2, MD, PhD; Andrés Iñiguez3, MD, PhD; Alberto SanRoman4, MD, PhD; Fernando Alfonso1, MD, PhD; Rosana Hernández-Antolín1, MD, PhD; Dominick J. Angiolillo1, MD, PhD; Camino Bañuelos1, MD; Javier Escaned1, MD, PhD; Nieves Gonzalo1, MD, PhD; Cristina Fernández1, MD, PhD; Carlos Macaya1, MD, PhD; Manel Sabaté5*, MD, PhD; for the DIABETES Investigators
1. Servicio de Cardiología, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; 2. “Prínceps d’Espanya” University Hospital, Barcelona, Spain; 3. Meixoeiro University Hospital, Vigo, Spain; 4. H
Aims: The DIABETES (DIABETes and sirolimus-Eluting Stent) trial is a prospective, multicentre, randomised, controlled trial aimed at demonstrati